{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:01:01Z","timestamp":1788368461300,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC-2023-2778808"],"award-info":[{"award-number":["RC-2023-2778808"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports\u00ae"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ekir.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T12:56:54Z","timestamp":1704891414000},"page":"982-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["\u201cEculizumab First\u201d in the Management of Posttransplant Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"9","author":[{"given":"Federica","family":"Maritati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Cuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Busutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tondolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Zappulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella","family":"Vischini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Iacovella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Abenavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fabbrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Comai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.01.013_bib1","first-page":"28","article-title":"Thrombotic microangiopathy in renal transplantation","volume":"7","author":"Chiurchiu","year":"2002","journal-title":"Ann Transplant"},{"key":"10.1016\/j.ekir.2024.01.013_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.ekir.2024.01.013_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.01.013_bib4","article-title":"Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity","volume":"8","author":"Avila","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2024.01.013_bib5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.01.013_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.01.013_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.01.013_bib8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.01.013_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.01.013_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MNH.0b013e328365b3fe","article-title":"Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"22","author":"Noris","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2024.01.013_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib12","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/ckj\/sfaa096","article-title":"Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study","volume":"14","author":"Portoles","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2024.01.013_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.01.013_bib15","article-title":"Thrombotic microangiopathy in the renal allograft: results of the TMA Banff working group consensus on pathologic diagnostic criteria","volume":"36","author":"Afrouzian","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2024.01.013_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.01.013_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.01.013_bib18","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/TP.0000000000004585","article-title":"TMA in kidney transplantation","volume":"107","author":"Imanifard","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.01.013_bib19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.01.013_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP67335","article-title":"De novo thrombotic microangiopathy. An underrated complication of renal transplantation","volume":"67","author":"Ponticelli","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00007890-200203150-00017","article-title":"De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination","volume":"73","author":"Langer","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.01.013_bib22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2024.01.013_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib24","article-title":"De novo atypical haemolytic uremic syndrome after kidney transplantation","volume":"2018","author":"Devresse","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.01.013_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.transproceed.2016.11.008","article-title":"Eculizumab and Belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report","volume":"49","author":"Dedhia","year":"2017","journal-title":"Transplant Proc"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2024.01.013_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nep.12768","article-title":"Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab","volume":"21","author":"Ikeda","year":"2016","journal-title":"Nephrol (Carlton)"},{"key":"10.1016\/j.ekir.2024.01.013_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.01.013_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.01.013_bib31","article-title":"Clinicopathologic implications of complement genetic variants in kidney transplantation","volume":"8","author":"Ren","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2024.01.013_bib32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.01.013_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13903","article-title":"Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report","volume":"25","author":"Sanchez-Moreno","year":"2021","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ekir.2024.01.013_bib34","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/ctr.12453","article-title":"Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or Belatacept in renal transplant recipients","volume":"28","author":"Mulgaonkar","year":"2014","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.01.013_bib35","first-page":"218","article-title":"The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients","volume":"76","author":"Sahin","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib36","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib37","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2024.01.013_bib38","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.01.013_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/ctr.12170","article-title":"Successful conversion to Belatacept after thrombotic microangiopathy in kidney transplant patients","volume":"27","author":"Koppula","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2024.01.013_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/260254","article-title":"Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy","volume":"2013","author":"Cicora","year":"2013","journal-title":"Case Rep Med"},{"key":"10.1016\/j.ekir.2024.01.013_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semnephrol.2022.01.006","article-title":"The complement system in the modern era of kidney transplantation: mechanisms of injury and targeted therapies","volume":"42","author":"Kamel","year":"2022","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-018-0071-x","article-title":"The multifaceted role of complement in kidney transplantation","volume":"14","author":"Biglarnia","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.01.013_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cll.2018.10.004","article-title":"Complement and transplantation: from new mechanisms to potential biomarkers and novel treatment strategies","volume":"39","author":"Horwitz","year":"2019","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.ekir.2024.01.013_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ackd.2019.12.002","article-title":"Complement-based therapy in the management of antibody-mediated rejection","volume":"27","author":"Bhalla","year":"2020","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["Kidney International Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:28:32Z","timestamp":1766449712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2468024924000147"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.01.013","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cEculizumab First\u201d in the Management of Posttransplant Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports\u00ae","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}